Citius Oncology (CTOR) Cash & Equivalents (2022 - 2026)

Citius Oncology's Cash & Equivalents history runs 5 years deep, the most recent figure standing at $2.6 million for Q1 2026.

• In Q1 2026, Cash & Equivalents rose 2350466.07% year-over-year to $2.6 million; the TTM figure through Mar 2026 stood at $2.6 million (up 2350466.07% YoY), while the FY2025 annual figure was $3.9 million, up 3504282.14% from the prior year.
• Cash & Equivalents was $2.6 million for Q1 2026 at Citius Oncology, down from $7.3 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $7.3 million in Q4 2025 to a low of $112.0 in Q3 2024.
• Historically, Cash & Equivalents has averaged $1.2 million across 5 years, with a median of $76853.0 in 2023.
• Biggest YoY gain for Cash & Equivalents was 6513695.54% in 2025; the steepest drop was 99.66% in 2025.
• A 5-year view of Cash & Equivalents shows it stood at $289175.0 in 2022, then slumped by 90.83% to $26523.0 in 2023, then plunged by 99.58% to $112.0 in 2024, then jumped by 6513695.54% to $7.3 million in 2025, then tumbled by 63.91% to $2.6 million in 2026.
• The last three Cash & Equivalents figures came in at $2.6 million (Q1 2026), $7.3 million (Q4 2025), and $3.9 million (Q3 2025), per Business Quant data.